Physician profile
Victor Banzon
NPI 1225073547
$300,285.09
in general payments reported to CMS, 2019-2025
37 companies · $39K in 2025
The $39K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $8,696 · 2021: $39K · 2022: $60K · 2023: $18K · 2024: $54K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Travel and Lodging: $13K · Food and Beverage: $7,974 · Education: $2,626 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,045.00 |
| Travel and Lodging | $12,678.58 |
| Food and Beverage | $7,973.58 |
| Education | $2,626.37 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $121,048.97 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Mallinckrodt Enterprises LLC | $77,151.22 | 2019 | |
| Mallinckrodt Hospital Products INC. | $63,030.88 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,943.57 | 2019-2025 | Ofev, Jardiance |
| Intuitive Surgical, INC. | $4,910.30 | 2024-2025 | |
| Grifols USA, LLC | $3,940.63 | 2019-2024 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $1,154.72 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $666.96 | 2019-2025 | Xolair |
| Jazz Pharmaceuticals INC. | $448.01 | 2021-2024 | |
| Genzyme Corporation | $420.48 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $296.67 | 2020-2025 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $225.45 | 2019-2020 | |
| Lilly USA, LLC | $200.86 | 2025 | Zepbound |
| Harmony Biosciences LLC | $183.72 | 2023-2025 | Wakix |
| Merck Sharp & Dohme LLC | $178.97 | 2025 | Winrevair |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $147.06 | 2022 | |
| Ani Pharmaceuticals, INC. | $131.83 | 2023-2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | Dupixent |
| Janssen Pharmaceuticals, INC | $115.20 | 2019 | |
| Abbvie INC. | $109.19 | 2021-2025 | |
| Insmed, INC. | $101.83 | 2024-2025 | Arikayce, Brinsupri |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Verona Pharma, INC. | $85.53 | 2025 | Ohtuvayre |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.49 | 2019 | |
| Sunovion Pharmaceuticals INC. | $77.57 | 2019-2020 | |
| Tactile Systems Technology INC | $72.60 | 2024 | Entre Plus, Flexitouch Plus |
| Viatris Specialty LLC | $68.28 | 2025 | Yupelri |
| Mylan Specialty L.P. | $63.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.44 | 2019 | |
| Shire North American Group INC | $34.36 | 2019 | |
| Philips North America LLC | $32.28 | 2019-2020 | |
| United Therapeutics Corporation | $32.27 | 2025 | Tyvaso |
| Resmed Corp | $19.76 | 2024 | |
| Advanced Respiratory, INC | $16.70 | 2019 | |
| Nabriva Therapeutics, Plc | $15.71 | 2020 | |
| Electromed, INC. | $14.32 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Banzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.